IriSys clinical trial material manufacturing contract upped to $6m

By Melissa Fassbender

- Last updated on GMT

IriSys is responsible for formulation studies, process optimization, clinical dosage form manufacture, release testing, quality control, and quality assurance. (Image: iStock/Sergei_Aleshin)
IriSys is responsible for formulation studies, process optimization, clinical dosage form manufacture, release testing, quality control, and quality assurance. (Image: iStock/Sergei_Aleshin)

Related tags Pharmacology

IriSys LLC has been awarded an increase to its five-year prime vendor contract – an agreement now worth up to $6m.

The San Diego, California-based contract pharmaceutical product development and manufacturing services (CDMO) company was awarded the contract by the National Cancer Institute (NCI)'s Developmental Therapeutics Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD).

The original contract was awarded in 2015 and will continue through 2020.

This is the second five-year prime vendor contract that IriSys has received; the first was in place from 2010 until 2015, when the second contract was awarded​,” Louis Scotti, vice president, business development at IriSys told Outsourcing-Pharma.com.

Per the contract, IriSys will continue to manufacture oral, topical, and injectable dosage forms for NCI-sponsored and/or investigator-initiated clinical trials.

IriSys will be creating and improving (where necessary) formulations of drugs that the NCI has selected for clinical trials​,” said Scotti.

IriSys has the capacity for the envisioned work, Scotti explained, as the company recently doubled its capacity after moving into a new facility in 2015, at which time the company also increased its scientific staff by 60%.

However, IriSys is willing and prepared to invest in additional capacity should new contracts from commercial biopharma companies and the NIH/NCI require such capacity expansion​,” he added.

All work will be carried at the company’s 24,500 sq. ft. facility in San Diego.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars